AbbVie struck a licensing and development deal in China with Zelgen Biopharmaceuticals for a clinical‑stage DLL3‑targeted T‑cell engager. The agreement grants AbbVie rights to develop and commercialize the candidate in Greater China, leveraging Zelgen’s DLL3 program aimed at neuroendocrine and small cell tumor targets. The pact expands AbbVie’s oncology immunotherapy footprint in Asia and reflects continued industry appetite for T‑cell engagers in solid tumors. Financial terms and milestone structure were disclosed by the parties, and the program will progress under a joint development plan aligned with regional regulatory requirements.